DaVita Share Holder Equity 2012-2025 | DVA

DaVita share holder equity from 2012 to 2025. Share holder equity can be defined as the sum of preferred and common equity items
  • DaVita share holder equity for the quarter ending December 31, 2025 was $-0.304B, a 151.86% decline year-over-year.
  • DaVita share holder equity for 2025 was $-0.374B, a 194.41% decline from 2024.
  • DaVita share holder equity for 2024 was $0.396B, a 68.18% decline from 2023.
  • DaVita share holder equity for 2023 was $1.244B, a 42.03% increase from 2022.
DaVita Annual Share Holder Equity
(Millions of US $)
2025 $-374
2024 $396
2023 $1,244
2022 $876
2021 $936
2020 $1,567
2019 $2,319
2018 $3,908
2017 $4,886
2016 $4,850
2015 $5,084
2014 $5,360
2013 $4,606
2012 $3,917
2011 $2,268
DaVita Quarterly Share Holder Equity
(Millions of US $)
2025-09-30 $-304
2025-06-30 $-108
2025-03-31 $-7
2024-12-31 $396
2024-09-30 $587
2024-06-30 $850
2024-03-31 $1,133
2023-12-31 $1,244
2023-09-30 $1,379
2023-06-30 $1,206
2023-03-31 $1,020
2022-12-31 $876
2022-09-30 $702
2022-06-30 $775
2022-03-31 $1,018
2021-12-31 $936
2021-09-30 $1,328
2021-06-30 $1,463
2021-03-31 $1,433
2020-12-31 $1,567
2020-09-30 $1,753
2020-06-30 $2,334
2020-03-31 $2,133
2019-12-31 $2,319
2019-09-30 $2,513
2019-06-30 $4,243
2019-03-31 $4,087
2018-12-31 $3,908
2018-09-30 $4,029
2018-06-30 $4,485
2018-03-31 $4,782
2017-12-31 $4,886
2017-09-30 $4,969
2017-06-30 $5,272
2017-03-31 $5,341
2016-12-31 $4,850
2016-09-30 $5,119
2016-06-30 $4,959
2016-03-31 $4,922
2015-12-31 $5,084
2015-09-30 $5,192
2015-06-30 $5,347
2015-03-31 $5,171
2014-12-31 $5,360
2014-09-30 $5,151
2014-06-30 $4,957
2014-03-31 $4,838
2013-12-31 $4,606
2013-09-30 $4,437
2013-06-30 $4,282
2013-03-31 $3,957
2012-12-31 $3,917
2012-09-30 $2,670
2012-06-30 $2,508
2012-03-31 $2,402
2011-12-31 $2,268
2011-09-30 $2,082
2011-06-30 $1,946
2011-03-31 $2,137
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $9.950B $13.643B
DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services. DaVita's Dialysis and related lab services business segment provides inpatient as well as outpatient dialysis services, routine laboratory testing for ESRD patients and management services to outpatient dialysis centers. The company's other ancillary services and strategic initiatives segment includes its international dialysis services, pharmacy services, infusion therapy services, disease management services, vascular access services, ESRD clinical research programs and physician services.
Stock Name Country Market Cap PE Ratio
Fresenius SE (FSNUY) Germany $34.042B 17.17
Quest Diagnostics (DGX) United States $23.013B 21.00
Elanco Animal Health (ELAN) United States $12.486B 26.18
Encompass Health (EHC) United States $11.082B 20.17
Chemed (CHE) United States $6.703B 23.54
Option Care Health (OPCH) United States $5.622B 23.93
RadNet (RDNT) United States $5.365B 183.00
LifeStance Health (LFST) United States $2.735B 0.00
Addus HomeCare (ADUS) United States $2.103B 21.72
Aveanna Healthcare Holdings (AVAH) United States $1.657B 20.87
U.S Physical Therapy (USPH) United States $1.322B 33.44
Pennant (PNTG) United States $1.106B 36.75
Astrana Health (ASTH) United States $1.057B 98.84
Daxor (DXR) United States $0.062B 0.00
MEDIROM Healthcare Technologies (MRM) Japan $0.038B 0.00
Psychemedics (PMD) United States $0.000B 0.00